Filing Details

Accession Number:
0000905718-17-000867
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-10-04 16:02:40
Reporting Period:
2017-10-02
Accepted Time:
2017-10-04 16:02:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1042074 Cymabay Therapeutics Inc. CBAY Pharmaceutical Preparations (2834) 943103561
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1252524 Von Kurt Emster C/O Cymabay Therapeutics, Inc.
7999 Gateway Blvd, Suite 130
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2017-10-02 37,936 $7.93 1,350,940 No 4 S Indirect See Footnote
Common Stock Disposition 2017-10-03 70,940 $7.81 1,280,000 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 90,000 Direct
Common Stock 17,236 Indirect By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.83 to $8.07 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
  2. Shares are held by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth Bioequities Master Fund Limited ("ABE" and collectively with ABV VI the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.61 to $8.02 per share, inclusive. Reporting Person undertakes to provide to CymaBay, any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.